Company Reports

Recent Updates

All Reports

Company Report

Cencora is one of three leading domestic wholesalers of branded, generic, and specialty pharmaceutical products. With roughly $300 billion in annual US healthcare distribution sales, Cencora accounts for about a third of the domestic drug distribution market. Its two close competitors are Cardinal Health and McKesson, and the three operate as a pharmaceutical wholesale and distribution oligopoly, supplying over 90% of the US market.
Company Report

Cencora is one of three leading domestic wholesalers of branded, generic, and specialty pharmaceutical products. With roughly $300 billion in annual US healthcare distribution sales, Cencora accounts for about a third of the domestic drug distribution market. Its two close competitors are Cardinal Health and McKesson, and the three operate as a pharmaceutical wholesale and distribution oligopoly, supplying over 90% of the US market.
Company Report

Cencora is one of three leading domestic wholesalers of branded, generic, and specialty pharmaceutical products. With roughly $300 billion in annual US healthcare distribution sales, Cencora accounts for about a third of the domestic drug distribution market. Its two close competitors are Cardinal Health and McKesson, and the three operate as a pharmaceutical wholesale and distribution oligopoly, supplying over 90% of the US market.
Stock Analyst Note

Cencora delivered 3.8% and 7.5% revenue and adjusted EPS growth, respectively, during the fiscal second quarter. Both figures landed behind FactSet consensus. Revenue guidance was lowered to 5% growth at the midpoint from the previous 8%. Shares are down 14% at time of writing May 6.
Company Report

Cencora is one of three leading domestic wholesalers of branded, generic, and specialty pharmaceutical products. With roughly $300 billion in annual US healthcare distribution sales, Cencora accounts for about a third of the domestic drug distribution market. Its two close competitors are Cardinal Health and McKesson, and the three operate as a pharmaceutical wholesale and distribution oligopoly, supplying over 90% of the US market.
Company Report

Cencora is one of three leading domestic wholesalers of branded, generic, and specialty pharmaceutical products. With roughly $300 billion in annual US healthcare distribution sales, Cencora supplies about a third of the domestic drug distribution market. Its two close competitors are Cardinal Health and McKesson; the three operate as a pharmaceutical wholesale and distribution oligopoly, supplying over 90% of the US market.
Stock Analyst Note

Cencora announced it will acquire the majority of the outstanding equity interest of OneOncology for roughly $5 billion. Cencora and TPG formed a joint venture to initially acquire OneOncology together in June 2023. Cencora at the time paid $720 million to acquire 35% of the JV.
Company Report

Cencora is one of three leading domestic wholesalers of branded, generic, and specialty pharmaceutical products. With roughly $300 billion in annual US healthcare distribution sales, Cencora supplies about a third of the domestic drug distribution market. Its two close competitors are Cardinal Health and McKesson; the three operate as a pharmaceutical wholesale and distribution oligopoly, supplying over 90% of the US market.
Company Report

Cencora is one of three leading domestic wholesalers of branded, generic, and specialty pharmaceutical products. With over $250 billion in annual US healthcare distribution sales, the company supplies about a third of the domestic drug distribution market. Its two close competitors are Cardinal Health and McKesson; the three operate as a pharmaceutical wholesale and distribution oligopoly, supplying over 90% of the US market.
Company Report

Cencora is one of three leading domestic wholesalers of branded, generic, and specialty pharmaceutical products. With over $250 billion in annual US healthcare distribution sales, the company supplies about a third of the domestic drug distribution market. Its two close competitors are Cardinal Health and McKesson, and the three operate as a pharmaceutical wholesale and distribution oligopoly, supplying over 90% of the US market.
Stock Analyst Note

Narrow-moat Cencora reported strong second-quarter results and demonstrated healthy growth momentum. Total revenue of $75.5 billion was up 10.3% year over year and came in above our expectations. Favorable utilization trends and solid broad-based prescription upticks continue to propel Cencora’s performance in the midst of uncertainty due to tariffs and personnel changes at key regulatory authorities. Sales from GLP-1s (diabetes and weight-loss drugs) increased $2.2 billion, or up 36% against last year, and contributed about 30% of enterprise growth. Against the backdrop of positive performance, management raised EPS guidance about 2.5% at the midpoint, with roughly one third of the increase coming from acquisition and the rest from core distribution strength. After ticking up our near-term assumptions and baking in the acquisition, we raise our fair value estimate to $260 per share from $242.
Company Report

Cencora is one of three leading domestic wholesalers of branded, generic, and specialty pharmaceutical products. With over $250 billion in annual US healthcare distribution sales, the firm supplies about a third of the domestic drug distribution market. Its two close competitors are Cardinal Health and McKesson. Together, the three operate as a pharmaceutical wholesale and distribution oligopoly, supplying over 90% of the US market.
Stock Analyst Note

Narrow-moat Cencora started the year on a strong footing after delivering solid first-quarter results. Total sales of $81.5 billion were up 12.8% year over year and came ahead of our $78.1 billion estimate. Momentum in utilization trends remains strong and helped offset declining contributions from covid vaccines and therapies. Adjusted EPS of $3.73 also came in better than our $3.54 estimate. Against the backdrop of a positive readout as well as baking in RCA acquisition impact, management ticked up guidance for both revenue and adjusted operating income. After raising our near-term estimates and accounting for the time value of money, we raise our fair value estimate to $242 per share from $230; shares are fairly valued in 3-star territory.

Sponsor Center